PATENT CLAIM ANALYSIS

Application Number: 16166292
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["435", "007920"]

Abstract:
Certain embodiments are directed to method of measuring fortilin in a serum sample as a biomarker of in vivo apoptosis, which can be utilized to noninvasively assess the status of in vivo apoptosis in a subject.

Claim (Index 7):
The method of  claim 5 , wherein the disease or condition is cachexia, skeletal muscle atrophy associated with aging (sarcopenia), skeletal muscle atrophy associated with starvation, skeletal muscle atrophy associated with denervation, skeletal muscle atrophy associated with disuse, and skeletal muscle atrophy associated with inflammation.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 97.0
- Lexical Diversity: 1.35714
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['10021753', '12511478', '13443462', '15257669', '12515770']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5853502272141099
- 35 USC 102 Novelty (BERT): 0.5237781976563818
- Combined Prediction Score: 0.5791930242583371
- Mean Citation Score: 217.698576
- Max Citation Score: 242.66211
- Similarity Product: 114.86487354912045

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test